Advertisement

Topics

Latest "Daiichi Pharmaceutical" News Stories

09:58 EST 14th December 2018 | BioPortfolio

Here are the most relevant search results for "Daiichi Pharmaceutical" found in our extensive news archives from over 250 global news sources.

More Information about Daiichi Pharmaceutical on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Daiichi Pharmaceutical for you to read. Along with our medical data and news we also list Daiichi Pharmaceutical Clinical Trials, which are updated daily. BioPortfolio also has a large database of Daiichi Pharmaceutical Companies for you to search.

Showing "Daiichi Pharmaceutical" News Articles 1–25 of 8,900+

Relevant

Deals this week: Daiichi Sankyo, MannKind, Dova Pharmaceuticals

Daiichi Sankyo has transferred 41 of its long-listed products to Alfresa Pharma. The transaction also includes products manufactured by Daiichi...Read More... The post Deals this week: Daiichi Sankyo, MannKind, Dova Pharmaceuticals appeared first on Pharmaceutical Technology.


Kitasato Daiichi Sankyo Vaccine to merge with Daiichi Sankyo

Daiichi Sankyo Company, Limited announced the scheme for the reorganization of Kitasato Daiichi Sankyo Vaccine Co, Ltd, a subsidiary of Daiichi Sankyo, into a subsidiary specializing in manufacturing as of

Daiichi Sankyo transfers 41 products to Alfresa Pharma

Daiichi Sankyo has announced plans to split and transfer its inventories to Alfresa Pharma, along with Japanese manufacturing and sales...Read More... The post Daiichi Sankyo transfers 41 products to Alfresa Pharma appeared first on Pharmaceutical Technology.


Daiichi Sankyo and Roche to Collaborate on New HER2 Low Companion Diagnostic Test

TOKYO and MUNICH and BASKING RIDGE, New Jersey, Nov. 27, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into an agreement with...

EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib

Daiichi Sankyo’s pivotal data presentation at this year’s European Hematology Association (EHA) annual meeting showed that its FLT3 inhibitor quizartinib...Read More... The post EHA 2018: pivotal Phase III data for Daiichi Sankyo’s quizartinib appeared first on Pharmaceutical Technology.

Daiichi Sankyo’s lymphoma therapy gets orphan drug status in Japan

Daiichi Sankyo has secured orphan drug designation from the Japan Ministry of Health, Labour and Welfare (MHLW) for its axicabtagene...Read More... The post Daiichi Sankyo’s lymphoma therapy gets orphan drug status in Japan appeared first on Pharmaceutical Technology.

Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients ...

TOKYO and MUNICH and BASKING RIDGE, N.J., Oct. 21, 2018 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that updated phase 1 safety Read more...

Glycotope GmbH: Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

TOKYO, BERLIN, BASKING RIDGE, NJ / ACCESSWIRE / July 30, 2018 / Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Glycotope GmbH (hereafter, Glycotope) have entered into an exclusive ...

Deals this week: Mylan, Daiichi Sankyo, Takeda

Mylan has formed a partnership with Atomo Diagnostics to expand access to HIV self-testing products in developing and under-developed countries....Read More... The post Deals this week: Mylan, Daiichi Sankyo, Takeda appeared first on Pharmaceutical Technology.

Daiichi's AML drug granted FDA breakthrough status

Daiichi Sankyo's quizartinib, being developed to treat patients with relapsed or refractory acute myeloid leukemia with an FL -More- 

FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

Tokyo, Munich and Basking Ridge, NJ – (November 21, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted...

Daiichi to test cancer drug combo

Daiichi Sankyo has entered into a clinical trial collaboration agreement with a subsidiary of MSD to evaluate a potential new combination therapy for breast or lung cancers.

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML

Tokyo, Munich and Basking Ridge, NJ – (August 1, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to quizartinib, an...

Daiichi-Merck partnership lines up Keytruda combo therapy

Daiichi Sankyo announced it has entered into a clinical trial collaboration agreement with Merck & Co. to evaluate an investigational lung cancer treatment.

Daiichi Sankyo Presents Phase 3 ENLIVEN Study of Pexidartinib, Demonstrating Statistically Significant Clinical Improvement Across Multiple Endpoints in Patients with Tenosynovial Giant Cell Tumor

Tokyo, Basking Ridge, NJ, and Munich – (June 4, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the phase 3 ENLIVEN study showed a statistically significant 39 percent overall response rate (ORR) at week...

Daiichi Sankyo forms partnership deals for DS-8201 trial

Daiichi Sankyo has collaborated with Merck and Pfizer for a Phase Ib clinical trial to investigate [fam-] trastuzumab deruxtecan (DS-8201)...Read More... The post Daiichi Sankyo forms partnership deals for DS-8201 trial appeared first on Drug Development Technology.

Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC

The deal combines Daiichi Sankyo’s ADC technology with Glycotope’s investigational tumor-associated TA-MUC1 antibody gatipotuzumab (formerly PankoMab-GEX), building on a previous 2017 option agreement. Under the terms of the The post Daiichi Sankyo signs licensing deal with Glycotope for Gatipotuzumab ADC appeared first on Pharma Business review.

Daiichi, Merck subsidiary partner on breast, lung cancer R&D

Daiichi Sankyo and a subsidiary of Merck, known as MSD outside North America, agreed to work together to develop the former's -More- 

Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201

Daiichi Sankyo Company has signed a clinical trial collaboration agreement with a Merck subsidiary to conduct a Phase lb trial...Read More... The post Daiichi Sankyo forms collaboration for Phase lb trial of DS-8201 appeared first on Drug Development Technology.

FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo’s Quizartinib for Relapsed/Refractory FLT3-ITD AML

Tokyo, Munich and Basking Ridge, NJ – (August 1, 2018) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to quizartinib, an investigational FLT3 inhibitor, for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia (AML). “There have been li...

Daiichi Sankyo reports positive results from Phase I/II U3-1402 trial

Daiichi Sankyo has reported new positive efficacy and safety results from its ongoing Phase I/II study of U3-1402 in heavily...Read More... The post Daiichi Sankyo reports positive results from Phase I/II U3-1402 trial appeared first on Drug Development Technology.

Daiichi Sankyo files NDA in Japan for leukemia drug quizartinib

A New Drug Application was submitted by Daiichi Sankyo with Japan's Ministry of Health, Labor and Welfare to obtain marketing -More- 

Daiichi Sankyo and Glycotope reach agreement for “first-in-class” ADC

Daiichi Sankyo and Glycotope have signed a licensing agreement to develop an antibody-drug conjugate that enables tumor-specific binding to TA-MUC1.

Daiichi Sankyo doses first patients in Phase lll trials for breast cancer

Daiichi Sankyo has dosed the first patients in two Phase lll DESTINY-Breast03 and DESTINY-Breast02 trials investigating the safety and efficacy...Read More... The post Daiichi Sankyo doses first patients in Phase lll trials for breast cancer appeared first on Drug Development Technology.

Press Release: Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate

Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate Tokyo, Berlin, Basking Ridge, NJ -- (July 30, 2018) -- Daiichi Sankyo Company, Limited ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks